BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220802T110000
DTEND;TZID=America/Toronto:20220802T114500
DTSTAMP:20260429T032412
CREATED:20220627T202034Z
LAST-MODIFIED:20220627T202034Z
UID:20627-1659438000-1659440700@scienceinboston.com
SUMMARY:American Heart Association Funding Webinar
DESCRIPTION:Learn about upcoming AHA Research award offerings\, application tips\, and the review process. Each webinar will consist of a 20-minute overview of the AHA Research award offerings\, plus a 10-minute Q & A session. These calls are a great opportunity for scientists\, researchers\, institutions\, and grant officers to get application questions answered.
URL:https://scienceinboston.com/event/american-heart-association-funding-webinar/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220802T110000
DTEND;TZID=America/Toronto:20220802T114500
DTSTAMP:20260429T032412
CREATED:20220627T202034Z
LAST-MODIFIED:20220627T202034Z
UID:27849-1659438000-1659440700@scienceinboston.com
SUMMARY:American Heart Association Funding Webinar
DESCRIPTION:Learn about upcoming AHA Research award offerings\, application tips\, and the review process. Each webinar will consist of a 20-minute overview of the AHA Research award offerings\, plus a 10-minute Q & A session. These calls are a great opportunity for scientists\, researchers\, institutions\, and grant officers to get application questions answered.
URL:https://scienceinboston.com/event/american-heart-association-funding-webinar-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220802T120000
DTEND;TZID=America/Toronto:20220802T130000
DTSTAMP:20260429T032412
CREATED:20220729T181012Z
LAST-MODIFIED:20220729T181029Z
UID:21012-1659441600-1659445200@scienceinboston.com
SUMMARY:Aging Brain Seminar with Hideyuki Okano
DESCRIPTION:*This seminar will be held in-person in MIT Building 46\, Room 46-3310 (Picower Seminar Room). If you are attending from outside of MIT\, please email Brittany Greenough at bgreeno@mit.edu to be issued a ticket to gain entry to the building.* \nTalk Title: Modeling neurological diseases using iPS cell technologies and genetically modified non-human primates \nAbstract: The investigation of human neurological/psychiatric disorders have been difficult based on the following reasons: i) Diseases Model Mice do not always recapitulate the pathophysiology of human diseases. ii) Genotype-Phenotype causal relationships are not always clear in many human neurological and psychiatric disorders. iii) It is extremely difficult to investigate what is taking place in vivo at the onset of the disease. iv) The low accessibility to the pathological foci in the human brain. v) The neuronal circuits responsible for the disease phenotypes are mostly unidentified. To overcome these\, we are taking advantage of Take the Advantage of iPS cell technology and genetically modified non-human primates. \nHuman iPS cell (iPSC)-based techniques offer new opportunities for disease modeling and the development of new drugs\, especially for conditions such as neurological and psychiatric diseases in which access to the affected cells and pathogenic sites is limited. So far\, we have established patient-specific iPSCs from more than 40 neurological and psychiatric diseases\, including amyotrophic lateral sclerosis (ALS)\, Alzheimer’s disease\, Parkinson’s disease\, and so on. Today\, I am going to focus on the iPSCs-based investigation of ALS\, which is a devastating neurodegenerative disease characterized by loss of upper motor neurons (MNs) and/or lower MNs (LMNs). Using iPSCs-MNs derived from familial ALS patients with FUS and TDP-43 mutations\, we could identify Ropinirole (ROPI: Already approved as an anti-PD drug with D2R agonist) as a potential anti-ALS Drug which is further being investigated as a clinical trial (ROPALS trial). As a result of the ROPALS trial\, we conclude that ROPI is a safe and effective drug for ALS patients. ROPI significantly suppressed the progression of ALS and prolonged the time to respiratory failure over the 1-year treatment period. This clinical trial proved that iPS cell drug discovery was useful as a new drug screening tool. \nThe common marmoset (Callithrix jacchus) is a small New World primate that has been extensively used in biomedical research models. There is also an increasing interest in common marmoset in Brain Science and as appropriate models for major human brain disorders (Okano\, Annual Rev Neurosci\, 2021). We succeeded in generating the world’s first genetically modified (GM) marmoset with germline transmission by lentiviral mediated transgenesis (Sasaki et al.\, Nature\, 2009) and genome-edited marmosets (GM) (Sato et al.\, Cell Stem Cell\, 2016). I wish to mention our recent data on the generation of transgenic marmoset models of neurodegenerative diseases\, including Parkinson’s disease (PD) which overexpressed the mutant form of a-synuclein using a lentiviral vector. The PD model marmoset showed stage-dependent progression of the disease\, such as sleeping disturbance followed by the motor deficit. In addition\, I will mention a model marmoset of a neurodevelopmental disorder\, the Rett syndrome\, obtained by genome editing of MECP2 gene. Abnormalities in brain structure and function in these marmoset models may accelerate the discovery of disease biomarkers and mechanisms for translation. \nBio: Hideyuki Okano received his M.D. in Physiology from Keio University in 1983. After he obtained a Ph.D. degree in Molecular Biology of Myelin-related genes and myelin deficient mutant mice from Keio University in 1988\, he held a post-doctoral position at Dr. Craig Montell’s Lab at Johns Hopkins University School of Medicine. He was appointed full professor at Tsukuba University School of Medicine in 1994\, Osaka University School of Medicine in 1997\, and returned to Keio University Medical School in 2001 as a full professor of Physiology. Since 2007\, he has been a Dean of Keio University Graduate School of Medicine or a Dean of Keio University School of Medicine. He has been conducting basic research in the field of regenerative medicine including\, neural stem cells and iPS cells\, spinal cord injury\, developmental genetics\, and RNA binding proteins. He has been awarded a number of awards and honors including the Medal with Purple Ribbon in 2009\, the first prize of the 51st Erwin von Bälz Prize in 2014\, the 18th Takamine Memorial Daiichi Sankyo Prize in 2020\, and the Uehara Prize in 2021. He aims to establish and provide patient-specific iPS cells and genetically modified non-human primate models for neuroscience research and to explore the pathogenic mechanisms of neurological/psychiatric disorders. Currently\, he is the leader of the Brain Project in Japan (Brain/MINDS) and the President of The Japanese Society for Regenerative Medicine and The Japanese Society for Neurochemistry. \nThe Aging Brain Initiative is an interdisciplinary effort by MIT focusing on understanding neurodegeneration and discovery efforts to find hallmarks of aging\, both in health and disease.
URL:https://scienceinboston.com/event/aging-brain-seminar-with-hideyuki-okano/
LOCATION:MIT\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220802T120000
DTEND;TZID=America/Toronto:20220802T130000
DTSTAMP:20260429T032412
CREATED:20220729T181012Z
LAST-MODIFIED:20220729T181012Z
UID:27856-1659441600-1659445200@scienceinboston.com
SUMMARY:Aging Brain Seminar with Hideyuki Okano
DESCRIPTION:*This seminar will be held in-person in MIT Building 46\, Room 46-3310 (Picower Seminar Room). If you are attending from outside of MIT\, please email Brittany Greenough at bgreeno@mit.edu to be issued a ticket to gain entry to the building.* \nTalk Title: Modeling neurological diseases using iPS cell technologies and genetically modified non-human primates \nAbstract: The investigation of human neurological/psychiatric disorders have been difficult based on the following reasons: i) Diseases Model Mice do not always recapitulate the pathophysiology of human diseases. ii) Genotype-Phenotype causal relationships are not always clear in many human neurological and psychiatric disorders. iii) It is extremely difficult to investigate what is taking place in vivo at the onset of the disease. iv) The low accessibility to the pathological foci in the human brain. v) The neuronal circuits responsible for the disease phenotypes are mostly unidentified. To overcome these\, we are taking advantage of Take the Advantage of iPS cell technology and genetically modified non-human primates. \nHuman iPS cell (iPSC)-based techniques offer new opportunities for disease modeling and the development of new drugs\, especially for conditions such as neurological and psychiatric diseases in which access to the affected cells and pathogenic sites is limited. So far\, we have established patient-specific iPSCs from more than 40 neurological and psychiatric diseases\, including amyotrophic lateral sclerosis (ALS)\, Alzheimer’s disease\, Parkinson’s disease\, and so on. Today\, I am going to focus on the iPSCs-based investigation of ALS\, which is a devastating neurodegenerative disease characterized by loss of upper motor neurons (MNs) and/or lower MNs (LMNs). Using iPSCs-MNs derived from familial ALS patients with FUS and TDP-43 mutations\, we could identify Ropinirole (ROPI: Already approved as an anti-PD drug with D2R agonist) as a potential anti-ALS Drug which is further being investigated as a clinical trial (ROPALS trial). As a result of the ROPALS trial\, we conclude that ROPI is a safe and effective drug for ALS patients. ROPI significantly suppressed the progression of ALS and prolonged the time to respiratory failure over the 1-year treatment period. This clinical trial proved that iPS cell drug discovery was useful as a new drug screening tool. \nThe common marmoset (Callithrix jacchus) is a small New World primate that has been extensively used in biomedical research models. There is also an increasing interest in common marmoset in Brain Science and as appropriate models for major human brain disorders (Okano\, Annual Rev Neurosci\, 2021). We succeeded in generating the world’s first genetically modified (GM) marmoset with germline transmission by lentiviral mediated transgenesis (Sasaki et al.\, Nature\, 2009) and genome-edited marmosets (GM) (Sato et al.\, Cell Stem Cell\, 2016). I wish to mention our recent data on the generation of transgenic marmoset models of neurodegenerative diseases\, including Parkinson’s disease (PD) which overexpressed the mutant form of a-synuclein using a lentiviral vector. The PD model marmoset showed stage-dependent progression of the disease\, such as sleeping disturbance followed by the motor deficit. In addition\, I will mention a model marmoset of a neurodevelopmental disorder\, the Rett syndrome\, obtained by genome editing of MECP2 gene. Abnormalities in brain structure and function in these marmoset models may accelerate the discovery of disease biomarkers and mechanisms for translation. \nBio: Hideyuki Okano received his M.D. in Physiology from Keio University in 1983. After he obtained a Ph.D. degree in Molecular Biology of Myelin-related genes and myelin deficient mutant mice from Keio University in 1988\, he held a post-doctoral position at Dr. Craig Montell’s Lab at Johns Hopkins University School of Medicine. He was appointed full professor at Tsukuba University School of Medicine in 1994\, Osaka University School of Medicine in 1997\, and returned to Keio University Medical School in 2001 as a full professor of Physiology. Since 2007\, he has been a Dean of Keio University Graduate School of Medicine or a Dean of Keio University School of Medicine. He has been conducting basic research in the field of regenerative medicine including\, neural stem cells and iPS cells\, spinal cord injury\, developmental genetics\, and RNA binding proteins. He has been awarded a number of awards and honors including the Medal with Purple Ribbon in 2009\, the first prize of the 51st Erwin von Bälz Prize in 2014\, the 18th Takamine Memorial Daiichi Sankyo Prize in 2020\, and the Uehara Prize in 2021. He aims to establish and provide patient-specific iPS cells and genetically modified non-human primate models for neuroscience research and to explore the pathogenic mechanisms of neurological/psychiatric disorders. Currently\, he is the leader of the Brain Project in Japan (Brain/MINDS) and the President of The Japanese Society for Regenerative Medicine and The Japanese Society for Neurochemistry. \nThe Aging Brain Initiative is an interdisciplinary effort by MIT focusing on understanding neurodegeneration and discovery efforts to find hallmarks of aging\, both in health and disease.
URL:https://scienceinboston.com/event/aging-brain-seminar-with-hideyuki-okano-2/
LOCATION:MIT\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220811T170000
DTEND;TZID=America/Toronto:20220811T190000
DTSTAMP:20260429T032412
CREATED:20220705T172603Z
LAST-MODIFIED:20220705T172849Z
UID:20672-1660237200-1660244400@scienceinboston.com
SUMMARY:STAT Locals
DESCRIPTION:STAT Locals are free in-person meet ups hosted by STAT. STAT Locals proudly have no programming; they are free happy hour events\, produced by STAT\, meant to help spark new connections and collaborations within the life science communities we report on. \nAugust 11: STAT Locals for the biotech community in Greater Boston (Boston & Cambridge).
URL:https://scienceinboston.com/event/stat-locals/
LOCATION:Cambridge Brewing Co.\, Kendall Square\, 1 Kendall Square\, Bldg 100\, Cambridge\, MA\, 02139\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2022/07/Logo-on-light-1.png
ORGANIZER;CN="STAT News":MAILTO:stat.community@statnews.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220811T170000
DTEND;TZID=America/Toronto:20220811T190000
DTSTAMP:20260429T032412
CREATED:20220705T172603Z
LAST-MODIFIED:20220705T172603Z
UID:27852-1660237200-1660244400@scienceinboston.com
SUMMARY:STAT Locals
DESCRIPTION:STAT Locals are free in-person meet ups hosted by STAT. STAT Locals proudly have no programming; they are free happy hour events\, produced by STAT\, meant to help spark new connections and collaborations within the life science communities we report on. \nAugust 11: STAT Locals for the biotech community in Greater Boston (Boston & Cambridge).
URL:https://scienceinboston.com/event/stat-locals-2/
LOCATION:Cambridge Brewing Co.\, Kendall Square\, 1 Kendall Square\, Bldg 100\, Cambridge\, MA\, 02139\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2022/07/Logo-on-light-1.png
ORGANIZER;CN="STAT News":MAILTO:stat.community@statnews.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220818T160000
DTEND;TZID=America/New_York:20220818T183000
DTSTAMP:20260429T032412
CREATED:20220805T222328Z
LAST-MODIFIED:20220805T222328Z
UID:21079-1660838400-1660847400@scienceinboston.com
SUMMARY:Bits in Bio @ Vertex
DESCRIPTION:Vertex is excited to host the next Bits in Bio meetup on their expanded terrace with a phenomenal seaport view! Come catch up and network with the Boston Bits in Bio community\, including engineers and scientists from Vertex who are eager to share how they are creating a cutting-edge technology environment to enable science at scale across the drug discovery pipeline. Food and drinks provided. \nLearn more about Vertex and open roles here: \n\nhttps://www.vrtx.com\nhttps://vrtx.wd5.myworkdayjobs.com/Vertex_Careers/job/Boston-MA/Computational-Chemistry-Senior-Principal-Research-Scientist–Software-Development-_REQ-15166\nhttps://vrtx.wd5.myworkdayjobs.com/Vertex_Careers/job/Boston-MA/Senior-Principal-Software-Engineer–Fullstack-_REQ-15192-1\n\nNote: All attendees must bring government issue ID\, and be vaccinated\, in order to enter the building.
URL:https://scienceinboston.com/event/bits-in-bio-vertex/
LOCATION:Vertex Pharmaceuticals\, 11 Fan Pier Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220818T160000
DTEND;TZID=America/New_York:20220818T183000
DTSTAMP:20260429T032412
CREATED:20220805T222328Z
LAST-MODIFIED:20220805T222328Z
UID:27857-1660838400-1660847400@scienceinboston.com
SUMMARY:Bits in Bio @ Vertex
DESCRIPTION:Vertex is excited to host the next Bits in Bio meetup on their expanded terrace with a phenomenal seaport view! Come catch up and network with the Boston Bits in Bio community\, including engineers and scientists from Vertex who are eager to share how they are creating a cutting-edge technology environment to enable science at scale across the drug discovery pipeline. Food and drinks provided. \nLearn more about Vertex and open roles here: \n\nhttps://www.vrtx.com\nhttps://vrtx.wd5.myworkdayjobs.com/Vertex_Careers/job/Boston-MA/Computational-Chemistry-Senior-Principal-Research-Scientist–Software-Development-_REQ-15166\nhttps://vrtx.wd5.myworkdayjobs.com/Vertex_Careers/job/Boston-MA/Senior-Principal-Software-Engineer–Fullstack-_REQ-15192-1\n\nNote: All attendees must bring government issue ID\, and be vaccinated\, in order to enter the building.
URL:https://scienceinboston.com/event/bits-in-bio-vertex-2/
LOCATION:Vertex Pharmaceuticals\, 11 Fan Pier Boulevard\, Boston\, MA\, 02210\, United States
END:VEVENT
END:VCALENDAR